PREADISAN offers a personalized health assessment platform that leverages proteomics and machine learning to provide a PREADISAN risk score. This score delivers health predictions and mortality risk assessments, primarily serving the insurance and financial services sectors.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional life expectancy assessments rely on statistical models that may not accurately reflect an individual's unique health status and biological factors. This can lead to imprecise risk evaluations in insurance and financial planning, potentially resulting in inadequate coverage or misinformed financial decisions.
Solution
Lorisco Life offers PREADISAN, a personalized health assessment platform that utilizes blood-based proteomics and machine learning to provide an individualized mortality risk score. PREADISAN integrates biological insights with AI models to assess the risk of mortality-impacting events, offering a novel tool for individualized planning in the financial services market. The platform analyzes proteomic biomarker data coupled with clinical data to deliver cutting-edge health predictions in an effective and secure manner. This enables insurance companies and financial services to develop tailored plans and superior coverage options based on a more precise understanding of individual health risks.
Target Audience
The primary target audience includes insurance companies and financial service providers seeking advanced tools for personalized risk assessment and tailored financial planning.
Features
- Blood-based proteomic biomarker analysis for personalized health risk assessment
- Clinically-driven AI models that assess the risk of mortality-impacting events
- Integration of biological insights with traditional risk assessment
- Secure and private data handling, prioritizing data security